$JNJ

Duato Joaquin sold $32.2M of JNJ

Duato Joaquin (CEO and Chairman of the Board) sold 123,291 shares of JOHNSON & JOHNSON (JNJ) at an average of $261.17 ($261.00–$262.00, $32.20M total) across 2 trades on 2026-08-13.

Original reporting
SEC EDGAR · Duato Joaquin
Published Aug 14, 2026, 8:35 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$JNJ
Neutral
low confidence
Mentioned
$JNJ
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$JNJNeutralLow
01

Why it matters

A CEO open-market sale of roughly $32.2M can create short-term negative optics, but it does not change fundamentals absent accompanying guidance, legal, or operational news.

02

Market read

Traders may monitor for follow-on insider activity or correlate with price/volume, but the filing does not provide new business information.

03

What to watch

No 10b5-1 plan is stated, but the filing alone does not reveal tax, estate, or diversification context, limiting inference quality.

Relevance 7/10Novelty 5/10Timing: filed 2026-08-14, sale executed 2026-08-13

Background

The article is an SEC Form 4 insider transaction disclosure for Johnson & Johnson.

Company-level read

Ticker impact

$JNJNeutralLow confidence
Context

SEC Form 4 shows CEO and Chairman Duato Joaquin sold 123,291 shares of JNJ for about $32.2M on 2026-08-13.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than earnings or guidance-driven.

Evidence & confidence

The filing is primary-source and material in size, but insider sales are often pre-planned or diversified and the text provides no new operational or financial information.

Market effects

No direct sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

The sale may reflect diversification or liquidity needs and does not necessarily signal reduced confidence, especially without evidence of a related negative event.

Key entities

  • Johnson & Johnson

    Subject of the Form 4 insider sale disclosure.

  • Duato Joaquin

    CEO and Chairman of the Board who sold shares via open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$JNJMedAI 8/10

J&J Gains as AbbVie Posts 74% Myeloma Response

J&J shares rose 1% to $277.955. AbbVie's experimental myeloma drug showed 74% response rate, 60% risk reduction. J&J's Carvykti drove 6.8% operational growth in Q2. Reuters notes AbbVie's drug complements, not replaces, J&J's treatment. J&J's stock is 44.08% above GF Value estimate.

$JNJMed

U.S. FDA warning prompts Taiwan red alert over heart pump device

Taiwan's FDA issued a red alert over a heart pump device after the U.S. FDA warned of a defect in Abiomed Inc.'s Automated Impella Controllers, linked to 3 deaths and 37 injuries. The device, used in 19 Taiwanese hospitals, is being recalled for a cartridge recognition issue. Johnson & Johnson MedTech, the local license holder, must notify providers and implement fixes.

$JNJHighAI 8/10

Johnson & Johnson cuts 2026, 2027 adjusted EPS guidance by up to $1.36

Johnson & Johnson revised its 2026 and 2027 adjusted EPS guidance downward, citing expected decreases in operational and adjusted metrics. For 2026, EPS is expected to decrease by $0.64, and for 2027, by $1.36. The company also announced a $5.5 billion settlement for talc-related claims, with the first payment of up to $3 billion due in 2027.

$JNJMedAI 8/10

Johnson & Johnson names Tom Cavanaugh as Innovative Medicine chairman

Johnson & Johnson (JNJ) appointed Tom Cavanaugh as Executive Vice President and Worldwide Chairman of its Innovative Medicine division, effective September 1, 2026. Cavanaugh succeeds Jennifer Taubert, who is retiring after 21 years. The division generated over $60 billion in annual revenue under Taubert's leadership. JNJ's shares rose 0.86% to $258.03 on Friday following two biotech acquisitions: a $1 billion cash deal for Firefly Bio and a $2.58 billion option to acquire Sail Biomedicines, whi